Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomaralimab Follow-up in MDS
NCT03337451Phase 2Completed
- Sponsor
- Opsona Therapeutics
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tomaralimab in myelodysplastic syndrome (MDS), sponsored by Opsona Therapeutics. Started Feb 2018; status: completed.
02
Drugs
tomaralimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03337451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337451.